EXECUTIVE BOARD 130th session Provisional agenda item 6.13
EB130/22 Add.1 1 December 2011
Report on financial and administrative implications for the Secretariat of resolutions proposed for adoption by the Executive Board or Health Assembly
1. Resolution: Substandard/spurious/falsely-labelled/falsified/counterfeit medical products 2. Linkage to the Programme budget 2012–2013 (see document A64/7 http://apps.who.int/gb/ebwha/pdf_files/WHA64/A64_7-en.pdf) Strategic objective(s): 11 Organization-wide expected result(s): 11.2 How would this resolution contribute to the achievement of the Organization-wide expected result(s)? It responds to the strategic approach outlined in expected result 11.1 regarding “substandard/spurious/falsely-labelled/falsified/counterfeit medical products”. Does the programme budget already include the products or services requested in this resolution? (Yes/no) No 3. Estimated cost and staffing implications in relation to the Programme budget (a) Total cost Indicate (i) the lifespan of the resolution during which the Secretariat’s activities would be required for implementation and (ii) the cost of those activities (estimated to the nearest US$ 10 000). (i) 3 years (covering the period 2012–2015) subject to the decision of the Health Assembly. (ii) Total: between US$ 3 560 000 and US$ 4 840 000 (staff: between US$ 2 720 000 and US$ 4 000 000; activities: US$ 840 000). Conservative estimation based on a single annual meeting of the Member State mechanism. This only covers the cost of activities for one meeting as the terms of reference still need to be confirmed. (b) Cost for the biennium 2012–2013 Indicate how much of the cost indicated in 3 (a) is for the biennium 2012–2013 (estimated to the nearest US$ 10 000) Total: between US$ 2 370 000 and US$ 3 230 000 (staff: between US$ 1 810 000 and US$ 2 670 000; activities US$ 560 000). Indicate at which levels of the Organization the costs would be incurred, identifying specific regions where relevant Headquarters
EB130/22 Add.1
Is the estimated cost fully included within the approved Programme budget 2012–2013? (Yes/no) No If “no”, indicate how much is not included. Between US$ 2 370 000 and US$ 3 230 000 (c) Staffing implications Could the resolution be implemented by existing staff? (Yes/no) No If “no” indicate how many additional staff – full-time equivalents – would be required, identifying specific regions and noting the necessary skills profile(s), where relevant. Two staff members in the professional and higher categories (grades P.4 and P.5) together with one staff member in the general services category (grade G.5). 4. Funding Is the estimated cost for the biennium 2012–2013 indicated in 3 (b) fully funded? (Yes/no) No If “no”, indicate the funding gap and how the funds would be mobilized (provide details of expected source(s) of funds). Between US$ 2 370 000 and US$ 3 230 000; source(s) of funds: It is likely that seed money will be needed in the form of voluntary contributions from interested Member States, as technical activities are currently not defined with enough detail to address donors. Also, the project falls outside the current scope of donors in the medicines area.
=
=
=
2